Literature DB >> 15057289

MGMT: its role in cancer aetiology and cancer therapeutics.

Stanton L Gerson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15057289     DOI： 10.1038/nrc1319

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  256 in total

1.  PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

Authors:  Brian McEllin; Cristel V Camacho; Bipasha Mukherjee; Brandon Hahm; Nozomi Tomimatsu; Robert M Bachoo; Sandeep Burma
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.

Authors:  A K Annamalai; A F Dean; N Kandasamy; K Kovacs; H Burton; D J Halsall; A S Shaw; N M Antoun; H K Cheow; R W Kirollos; J D Pickard; H L Simpson; S J Jefferies; N G Burnet; M Gurnell
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

3.  A rapid survival assay to measure drug-induced cytotoxicity and cell cycle effects.

Authors:  Chandni Valiathan; Jose L McFaline; Leona D Samson
Journal:  DNA Repair (Amst)       Date:  2011-11-30

4.  Chemotherapy: Lo and behold, a role for lomustine in acute myeloid leukemia?

Authors:  Frederick R Appelbaum
Journal:  Nat Rev Clin Oncol       Date:  2010-11       Impact factor: 66.675

5.  Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging.

Authors:  Won-Jin Moon; Jin Woo Choi; Hong Gee Roh; So Dug Lim; Young-Cho Koh
Journal:  Neuroradiology       Date:  2011-08-11       Impact factor: 2.804

Review 6.  MGMT promoter methylation in malignant gliomas.

Authors:  Markus J Riemenschneider; Monika E Hegi; Guido Reifenberger
Journal:  Target Oncol       Date:  2010-08-20       Impact factor: 4.493

7.  Alkylation sensitivity screens reveal a conserved cross-species functionome.

Authors:  David Svilar; Madhu Dyavaiah; Ashley R Brown; Jiang-bo Tang; Jianfeng Li; Peter R McDonald; Tong Ying Shun; Andrea Braganza; Xiao-hong Wang; Salony Maniar; Claudette M St Croix; John S Lazo; Ian F Pollack; Thomas J Begley; Robert W Sobol
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

8.  Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.

Authors:  Antonio Silvani; Elena Lamperti; Paola Gaviani; Marica Eoli; Anna Fiumani; Andrea Salmaggi; Chiara Falcone; Graziella Filippini; Andrea Botturi; Amerigo Boiardi
Journal:  J Neurooncol       Date:  2007-06-19       Impact factor: 4.130

9.  Differential inactivation of polymorphic variants of human O6-alkylguanine-DNA alkyltransferase.

Authors:  Qingming Fang; Natalia A Loktionova; Robert C Moschel; Sahar Javanmard; Gary T Pauly; Anthony E Pegg
Journal:  Biochem Pharmacol       Date:  2007-10-02       Impact factor: 5.858

Review 10.  Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.

Authors:  Charles A Kunos; Evanthia Galanis; Jeffrey Buchsbaum; Qian Shi; Lewis C Strauss; C Norman Coleman; Mansoor M Ahmed
Journal:  J Neurooncol       Date:  2017-05-30       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.